Inhibition of diacylglycerol lipase β modulates lipid and endocannabinoid levels in the <i>ex vivo</i> human placenta.

ABSTRACT:

Introduction

Lipids and fatty acids are key components in metabolic processes of the human placenta, thereby contributing to the development of the fetus. Placental dyslipidemia and aberrant activity of lipases have been linked to diverse pregnancy associated complications, such as preeclampsia and preterm birth. The serine hydrolases, diacylglycerol lipase α and β (DAGLα, DAGLβ) catalyze the degradation of diacylglycerols, leading to the formation of monoacylglycerols (MAG), including one main endocannabinoid 2-arachidonoylglycerol (2-AG). The major role of DAGL in the biosynthesis of 2-AG is evident from various studies in mice but has not been investigated in the human placenta. Here, we report the use of the small molecule inhibitor DH376, in combination with the ex vivo placen

SUBMITTER: Berger N 

PROVIDER: S-EPMC9971001 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature